Britain and America have announced a significant bilateral deal that will guarantee no levies on UK pharmaceutical products entering the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has agreed to raise expenditure on pharmaceuticals through the public health system. This pledge ensures that tariffs on these vital products will remain at zero for a period of the next three years.
This development follows previous warnings to dramatically increase duties on patented pharmaceutical imports, with increases floated as high as 100%.
"This arrangement with the United Kingdom strengthens the international landscape for innovative medicines and establishes long-overdue equity to transatlantic medicine commerce," an announcement noted.
Trade Significance
Medicines constitute one of the UK's largest goods shipped to the United States, which is easily the largest buyer for major British pharmaceutical firms.
Statistics reveal that in the 12 months to the end of September, the UK sold pharmaceutical products valued at billions to the US. This amount made up nearly one-fifth of all goods exports in that span.
"This deal protects jobs, boosts funding and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary remarked.
Key NHS Changes
The agreement involves several notable commitments from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to double total NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must pay back to the NHS to stay within budget will be restricted at 15%. In the past, refunds topped 20%.
Industry Background
This agreement takes place against a ongoing dispute between the drug companies and the ministers over drug pricing and NHS adoption.
The disagreement were heightened by claims that US patients were charged significantly more for the identical medicines than consumers in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while substantial investments have been pledged toward American operations.
One official publicly accepted that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the previous ten-year period.
